13 hrs ago
Chemical & Engineering News
Cystic Fibrosis Drug Combination May Be Counteracting Itself
Combination therapies are a promising strategy for correcting the most common gene mutation responsible for cystic fibrosis.
18 hrs ago
Tests suggest limitations to Vertex's cystic fibrosis treatment
Investors and patients were exuberant last month when Vertex Pharmaceuticals released results from clinical trials showing that cystic fibrosis patients' lung function improved on an experimental two-drug regimen.
20 hrs ago
Customer Interaction Solutions
Investor Alert: Class Action Lawsuit Against Vertex Pharmaceuticals...
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all purchasers of the common stock of Pharmaceuticals Incorporated between May 7, 2012 and May 29, 2012, inclusive .
Mon Jul 14, 2014
The Motley Fool
Up 33%: Is Vertex Pharmaceuticals Stock Overpriced?
Those positive data were a big reason why the stock is up 32% year-to-date. These trials-nicknamed "TRAFFIC" and "TRANSPORT" enrolled a total of 1,100 patients across 200 research centers.
Vertex to Announce Second Quarter 2014 Financial Results on July 29
Vertex Pharmaceuticals Incorporated will report its second quarter 2014 financial results on Tuesday, July 29, 2014 after the financial markets close.
Atlantis Computing(R) Announces Record 1H Bookings, Appoints New CEO
Atlantis Computing , the leading provider of Software-Defined Storage, today announced it has delivered record-breaking 1H bookings and its Board of Directors has appointed Jason Donahue as Chief Executive Officer, President, and member of the Board of Directors.
Fri Jul 11, 2014
The Motley Fool
1 Drug More Important to Gilead Than Sovaldi
Sales of the drug totaled more than $2.2 billion in its first quarter on the market, making it the fastest drug to ever reach billion-dollar blockbuster status, and one of the planet's top-selling drugs.
On the Move: Personnel moves in local life sciences industry
Here's a summary of recent personnel changes and board appointments announced at Massachusetts biotech, pharmaceutical and medical device companies: Arch Therapeutics in Wellesley, developer of the AC5 Surgical Hemostatic Device, a novel product aimed at controlling bleeding and fluid loss, has appointed Richard Davis as CFO and treasurer.
6 stocks going bananas this summer
It's been a "Planet of Boring Stocks" this summer so far for most investors, with the market just about dead flat.
Thu Jul 10, 2014
Vertex Announces Retirement of Peter Mueller, Ph.D.
Vertex Pharmaceuticals Incorporated today announced that Peter Mueller, Ph.D., Executive Vice President of Global Research and Development and Chief Scientific Officer, will retire after more than 10 years with the company.
Wed Jul 09, 2014
Vertex Pharmaceuticals Stock Rating Upgraded by TheStreet
The analysts wrote, "Vertex Pharmaceuticals has been upgraded by TheStreet Ratings from sell to hold.
Mon Jul 07, 2014
Vertex Pharmaceuticals Lowered to Market Perform at Oppenheimer
In other Vertex Pharmaceuticals news, Director Elaine Ullian sold 5,000 shares of Vertex Pharmaceuticals stock on the open market in a transaction that occurred on Tuesday, July 1st.
Fri Jul 04, 2014
Economy creates 288,000 jobs in June; Dow breaks 17,000 on news
The economy created a whopping 288,000 jobs in June, and in celebration, the Dow Jones industrial average surpassed 17,000 for the first time.
Thu Jul 03, 2014
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, MannKind,...
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.
Tue Jul 01, 2014
Banker & Tradesman
Batali Delivers Pizza To Fan Pier
Celebrity chef Mario Batali will open an 8,700-square-foot restaurant called Babbo Pizzeria next year at Eleven Fan Pier Boulevard in Boston.
Mon Jun 30, 2014
Vertex Submits sNDA to FDA for Use of KALYDECOA in People 18 and...
Vertex Pharmaceuticals has announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for the approval of KALYDECO A in people with cystic fibrosis ages 18 and older who have the R117H mutation in the cystic fibrosis transmembrane conductance regulator gene.
This treatment is not a cure for CF, but to see the real change in my own body is a miracle
I sat on my hospital bed shaking in the knowledge that this was a historic day for people with CF, their families, their friends and their medical workers worldwide.
Sat Jun 28, 2014
The Motley Fool
Why Vertex Pharmaceuticals, Integrys Energy Group, and Iron Mountain Soared Last Week
Even as most of the economic data released during the past several days confirmed favorable conditions going forward for the U.S. economy, investors aren't as certain about the prospects for the coming earnings season.
Fri Jun 27, 2014
Are Biotech Stocks Overdue for a Summer Pullback?
You will receive a download link right in your email inbox for each of the free reports that you choose.
The Motley Fool
Today's Top Biotech Stocks: Bristol-Myers Squibb, United Therapeutics and Vertex Pharmaceuticals
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Bristol-Myers Squibb ( Bristol-Myers is a fountain of good news this morning Shares of Bristol-Myers should move higher today following two pieces of good news on the regulatory front in the EU.